Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | ACHE | P22303 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13480686 | 0.88 | TSHR (0.61) | TSHRACHEMAOBSIGMAR1 | |
| SCHEMBL16039094 | 0.86 | ACHE (0.76) | TSHRACHESMPD1SIGMAR1LTA4H | |
| SCHEMBL29336578 | 0.85 | TSHR (0.69) | TSHRACHEKCNH2SMPD1SIGMAR1 | |
| SCHEMBL21070282 | 0.84 | TSHR (0.56) | TSHRACHEMAOBKCNH2SMPD1 | |
| SCHEMBL21069435 | 0.84 | TSHR (0.56) | TSHRACHEMAOBKCNH2SMPD1 | |
| SCHEMBL17193571 | 0.83 | TSHR (0.59) | TSHRACHESIGMAR1 | |
| SCHEMBL8699475 | 0.83 | TSHR (0.66) | TSHRACHEMAOBKCNH2SMPD1 | |
| SCHEMBL19715501 | 0.81 | TSHR (0.61) | TSHRACHESIGMAR1 | |
| SCHEMBL9760037 | 0.80 | TSHR (0.56) | TSHRACHE | |
| Hydrochloric Acid SCHEMBL19715538 | 0.80 | TSHR (0.59) | TSHRACHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655768-B2 | Galactose derivative, drug carrier and medicinal composition | NIPPON SHINYAKU CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20070244058-A1 | Galactose Derivative, Drug Carrier and Medicinal Composition | NIPPON SHINYAKU CO., LTD. (JP) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244058-A1 | Galactose Derivative, Drug Carrier and Medicinal Composition | GALK1, GALE, UGGT1 | TSHR 2018/4885ACHE 4400/4885MAOB 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.